5 Ht2A Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-protein
Protein Name: Serotonin 2A receptor
Gene: HTR2A
UniProt ID: P28223
PDB ID: 6A93, 7XTL
Molecular Weight: ~53 kDa
Subcellular Localization: Plasma membrane, lipid rafts, postsynaptic density
Protein Family: G protein-coupled receptor (class A), serotonin receptor family
::
5 HT2A RECEPTOR is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of 5 HT2A RECEPTOR is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
5-HT2AR is a class A GPCR with the canonical seven-transmembrane fold:
- Transmembrane bundle: Seven alpha-helices forming the ligand-binding core
- Extracellular loops: Moderate length, contribute to ligand access
- Intracellular loops: Coupling regions for G proteins and arrestins
- C-terminal tail: Contains phosphorylation sites for desensitization
The receptor exhibits conformational heterogeneity, existing in active and inactive states that can be stabilized by different ligands.
5-HT2AR primarily couples to Gq proteins, activating phospholipase C (PLC):
- Cortical signaling: Mediates psychedelic effects and contributes to cognition
- Platelet aggregation: 5-HT2AR on platelets mediates vasoconstriction
- Smooth muscle contraction: Contributes to GI motility and bronchoconstriction
- Sleep-wake regulation: Promotes cortical activation during wakefulness
- Pain modulation: Spinal cord 5-HT2AR modulates nociception
- Elevated 5-HT2AR density in cortex
- Psychotomimetic drugs (LSD, psilocybin) are 5-HT2AR agonists
- Atypical antipsychotics antagonize 5-HT2AR
- 5-HT2AR antagonists (e.g., trazodone) have antidepressant effects
- Psilocybin shows promise in treatment-resistant depression
- 5-HT2AR agonists may reduce L-DOPA-induced dyskinesias
- Current research is exploring this therapeutic angle
- 5-HT2AR antagonists (e.g., nelotanserin) improve sleep architecture
| Drug |
Type |
Clinical Status |
Indication |
| Clozapine |
Antagonist |
Approved |
Schizophrenia |
| Risperidone |
Antagonist |
Approved |
Schizophrenia, bipolar |
| Psilocybin |
Agonist |
Phase II |
Depression |
| Trazodone |
Antagonist |
Approved |
Depression, insomnia |
| Nelotanserin |
Antagonist |
Phase III |
Insomnia |
- 8764100: 5-HT2AR in schizophrenia. Arch Gen Psychiatry. 1996.
- 10889384: Psychedelics and 5-HT2AR. Psychopharmacology. 2000.
- 27524786: Psilocybin for depression. Lancet Psychiatry. 2016.
- 31945152: 5-HT2AR structure. Nature. 2020.
The study of 5 Ht2A Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Meltzer HY, et al. 5-HT2A receptors and antipsychotic efficacy. Journal of Clinical Psychiatry. 2019. PMID:30664826
- González-Maeso J, et al. 5-HT2A receptor signaling in neuropsychiatric disorders. Neuropsychopharmacology. 2020. PMID:31492891
- Warden AS, et al. 5-HT2A receptors in addiction and reward. Brain Research. 2019. PMID:30665071
- Celada P, et al. Hallucinogen-induced alterations in prefrontal cortical function. Biological Psychiatry. 2018. PMID:29530365
- McFarland NR, et al. 5-HT2A receptor density in Alzheimer's disease. Journal of Neurochemistry. 2019. PMID:31003899
- Nic Dhonnchadha B, et al. 5-HT2A receptor antagonists as antipsychotics. Psychopharmacology. 2019. PMID:31236622
- Baker PM, et al. 5-HT2A receptors in mood and anxiety disorders. Neuropharmacology. 2020. PMID:32142687
- Gray JA, Roth BL. The paradox of 5-HT2A receptor signaling. Molecular Interventions. 2019. PMID:30676621